S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
Buffett's company owns nearly 24% of Occidental Petroleum
NYSE:EHAB

Enhabit - EHAB Stock Forecast, Price & News

$13.82
+0.04 (+0.29%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$13.59
$13.91
50-Day Range
$13.32
$16.02
52-Week Range
$11.65
$25.25
Volume
384,352 shs
Average Volume
627,393 shs
Market Capitalization
$685.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Enhabit MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
19.4% Upside
$16.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Enhabit in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
27.63%
From $0.76 to $0.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

673rd out of 1,002 stocks

Home Health Care Services Industry

6th out of 9 stocks


EHAB stock logo

About Enhabit (NYSE:EHAB) Stock

Enhabit, Inc. is a leading healthcare provider that offers Medicare-certified skilled home health and hospice services in the United States. The company operates in two segments: Home Health and Hospice, providing services to adult patients needing care, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Enhabit's hospice services include in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and emotional and spiritual support.

Enhabit operates home health agencies in approximately 34 states, with a concentration in the southern half of the United States. As of March 31, 2022, Enhabit operates in 252 home health agencies and 99 hospice agencies across 34 states. Enhabit provides practices to treat chronic diseases and conditions, including diabetes, arthritis, hypertension,  Alzheimer's disease, spinal stenosis, low vision,  Parkinson's disease, complex wound care, osteoporosis, and chronic pain, along with disease-specific plans for patients with diabetes, post-orthopedic surgery or injury, congestive heart failure,  and respiratory diseases.

Enhabit started as HealthSouth, founded in 1984 by Beam Scrushy and Richard Scrushy. In the early 2000s, the company restructured and rebranded into Encompass Health after being caught up in an accounting scandal. In Q2 of 2022, Enhabit, the healthcare and hospice division, became an independent public company, having completed its spinoff from Encompass Health Corporation. 

Barb Jacobsmeyer was named President and CEO of Enhabit Home Health & Hospice in June 2021. Jacobsmeyer came to Enhabit from Encompass Health, where she served as the company's executive vice president of operations. 

In Q3 of 2022, Enhabit, Inc. announced the acquisition of Caring Hearts Hospice, a locally-owned hospice agency in Texas. The acquisition adds four hospice locations in Texas to Enhabit's existing presence in the state. Ehnabit continues to expand, setting aside approximately one hundred million dollars to fund future mergers and acquisitions. 

Enhabit, Inc. is committed to providing high-quality care and service to patients and their families, and its success is a testament to its dedicated team of healthcare professionals. Enhabit is well-positioned to meet the growing demand for healthcare services in the United States as a leading home health and hospice service provider. With its focus on patient care and commitment to excellence, Enhabit is poised to continue to grow and succeed in the years ahead.

Enhabit's commitment to quality care has not gone unnoticed, as they have received numerous awards and recognitions for their services. In 2021, they were named a HomeCare Elite Top Agency for the 15th year. This recognition is given to the top-performing home health agencies in the United States. They have also received a 5-star rating from the Centers for Medicare & Medicaid Services (CMS) for their home health services, indicating their high quality and patient satisfaction.

Enhabit's success can be attributed to its skilled and compassionate staff and dedication to providing comprehensive and individualized patient care. Enhabit also recognizes the importance of emotional and spiritual support for their patients and their families, particularly in hospice care. Their hospice services include pain and symptom management, spiritual counseling, palliative and dietary counseling, social worker visits, and bereavement counseling services to meet terminally ill patients and their families' individual physical, spiritual, emotional, and psychosocial needs.

Receive EHAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enhabit and its competitors with MarketBeat's FREE daily newsletter.

EHAB Stock News Headlines

Here’s Why You Should Acquire Enhabit (EHAB)
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Enhabit, Inc. (NYSE:EHAB) Q4 2022 Earnings Call Transcript
Credit Suisse Reaffirms Their Hold Rating on Enhabit, Inc (EHAB)
Enhabit: Q4 Earnings Snapshot
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Is Enhabit, Inc. (NYSE:EHAB) Trading At A 50% Discount?
Should You Consider Investing in Enhabit (EHAB)?
Analyst Ratings for Enhabit
What 4 Analyst Ratings Have To Say About Enhabit
See More Headlines
Receive EHAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enhabit and its competitors with MarketBeat's FREE daily newsletter.

EHAB Company Calendar

Last Earnings
2/14/2023
Today
3/28/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
10,593
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+19.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
9 Analysts

Profitability

Net Income
$62.50 million
Pretax Margin
8.63%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Cash Flow
$2.20 per share
Book Value
$17.59 per share

Miscellaneous

Free Float
N/A
Market Cap
$685.75 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Ms. Barbara Ann Jacobsmeyer B.S. (Age 57)
    M.A., P.T., Pres, CEO & Director
  • Ms. Crissy Buchanan Carlisle (Age 51)
    Chief Financial Officer
  • Mr. Dan Peoples
    Exec. VP of Sales & Marketing
  • Ms. Tanya R. Marion (Age 49)
    Chief HR Officer
  • Ms. Julie D. Jolley B.S.N. (Age 51)
    R.N., Exec. VP of Home Health & Hospice Operations
  • Ms. Jeanne Kalvaitis B.S.N.
    R.N., Exec. VP of Hospice Operations
  • Mr. Bud Langham M.B.A.
    P.T., Exec. VP of Clinical Excellence & Strategy













EHAB Stock - Frequently Asked Questions

Should I buy or sell Enhabit stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enhabit in the last year. There are currently 2 sell ratings, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EHAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EHAB, but not buy additional shares or sell existing shares.
View EHAB analyst ratings
or view top-rated stocks.

What is Enhabit's stock price forecast for 2023?

9 brokerages have issued 1 year price targets for Enhabit's stock. Their EHAB share price forecasts range from $12.00 to $20.00. On average, they expect the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 19.4% from the stock's current price.
View analysts price targets for EHAB
or view top-rated stocks among Wall Street analysts.

How have EHAB shares performed in 2023?

Enhabit's stock was trading at $13.16 at the beginning of the year. Since then, EHAB stock has increased by 5.0% and is now trading at $13.82.
View the best growth stocks for 2023 here
.

When is Enhabit's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our EHAB earnings forecast
.

How were Enhabit's earnings last quarter?

Enhabit, Inc. (NYSE:EHAB) announced its quarterly earnings results on Tuesday, February, 14th. The company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.07. The company earned $275.10 million during the quarter, compared to analyst estimates of $268.15 million. Enhabit had a net margin of 5.77% and a trailing twelve-month return on equity of 7.41%.

What guidance has Enhabit issued on next quarter's earnings?

Enhabit issued an update on its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided earnings per share (EPS) guidance of $0.50-$0.89 for the period, compared to the consensus earnings per share estimate of $1.14. The company issued revenue guidance of $1.11 billion-$1.14 billion, compared to the consensus revenue estimate of $1.11 billion.

What is Enhabit's stock symbol?

Enhabit trades on the New York Stock Exchange (NYSE) under the ticker symbol "EHAB."

Who are Enhabit's major shareholders?

Enhabit's stock is owned by many different retail and institutional investors. Top institutional investors include Systematic Financial Management LP (3.45%), Deutsche Bank AG (3.00%), Morgan Stanley (1.88%), Schroder Investment Management Group (1.81%), AQR Capital Management LLC (1.75%) and Epoch Investment Partners Inc. (1.74%). Insiders that own company stock include Barbara Ann Jacobsmeyer, Charles M Elson, Erin Hoeflinger, Gregory S Rush, Jeffrey Bolton, John E D D S Maupin Jr, Leo I Higdon Jr and Tanya Renee Marion.
View institutional ownership trends
.

How do I buy shares of Enhabit?

Shares of EHAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enhabit's stock price today?

One share of EHAB stock can currently be purchased for approximately $13.82.

How much money does Enhabit make?

Enhabit (NYSE:EHAB) has a market capitalization of $685.75 million and generates $1.08 billion in revenue each year.

How many employees does Enhabit have?

The company employs 10,593 workers across the globe.

How can I contact Enhabit?

The official website for the company is www.ehab.com. The company can be reached via phone at 214-239-6500 or via email at investorrelations@ehab.com.

This page (NYSE:EHAB) was last updated on 3/29/2023 by MarketBeat.com Staff